Nuwellis Inc (NASDAQ:NUWE) shares are surging Thursday afternoon as traders react to new pediatric data tied to the company’s Aquadex ultrafiltration therapy.
- Nuwellis stock is showing exceptional strength. What’s fueling NUWE momentum?
What Is Driving Nuwellis’ Stock Surge?
Nuwellis said a new single-center retrospective study supporting an alternative anticoagulation strategy for Aquadex ultrafiltration therapy was accepted by Frontiers in Pediatrics, highlighting epoprostenol as a potential option for keeping circuits open without adding bleeding risk or requiring intensive metabolic monitoring.
The company also noted it provided modest financial support to underwrite open-access publication costs, but did not fund the conduct of the research.
Nuwellis’ rally is also being framed by traders as a continuation of its pediatric push after it installed its first Aquadex SmartFlow systems at a leading pediatric hospital in Wisconsin.
That installation followed preliminary second-quarter revenue growth of 14% year over year (and 20% growth for the six-month period ended June 30), keeping attention on the Aug. 13 results date.
Nuwellis Stock Price Activity Update
NUWE Stock Price Activity: Nuwellis shares were up 136.77% at $4.48 at the time of publication on Thursday, according to Benzinga Pro data.
Image: Shutterstock
